Promyelocytic Leukemia, Acute Clinical Trial
Official title:
Results From a Mexican Long-term Multicentric Study on Acute Promyelocytic Leukemia.
Retrospective, observational study, comparing treatments of acute promyelocytic leukemia in
different centers in México.
There is no sufficient information about acute promyelocytic leukemia in America Latina,
particularly in Mexico.
For these reason the investigators started a study adding all promyelocityc patients from the
main Hospital in Mexico in order to put together a group of patient and analyze the response,
overall survival and what are the characteristics of the population.
The investigators included 5 Hospital in Mexico City and states as Monterrey, Guadalajara,
San Luis Potosi, Puebla, Veracruz, Yucatán, Oaxaca, Guanajuato, Estado de México.
Even do, the investigators didn´t have arsenic trioxide they are treating patients with
standard chemotherapy. These paper will help to show the authorities that the cost of
treating patient with standard chemotherapy is much more higher than ATO-ATRA. The
investigators are now doing a cost benefit analysis so the investigators, can soon have ATO
treatment as standard of care in Mexico for the treatment of acute promyelocytic leukemia.
A multicentric, retrospective, descriptive, longitudinal study was carried out. Between
January 2007 and January 2017, patients of both sexes and different ages, who were candidates
for receiving intensive chemotherapy along with tretinoin were included in the study. The
diagnosis for Acute Promyelocytic Leukemia was determined based on the following criteria:
abnormal promyelocytes in the bone marrow and verification of the t(15;17) translocation by
karyotype or using RT-PCR to determine the genetic lesion and define the type of PML/RARA
isoform.
In Mexico the investigators still treating patients with anthracycline and cytarabine +
transretinoic acid. These information will help the authorities to realize the importance of
having arsenic trioxide as part of the treatment of these disease, knowing the amount of
patient that the investigators have in Mexico, knowing that in the hispanic race the
incidence is greater.
;